# DIA_CENTRAL:T2D Treatment Pattern in Central Europe

> **NCT03807440** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 4083 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Sodium Glucose Transporter 2 inhibitor
- **DRUG:** Dipeptidyl-peptidase 4 inhibitor
- **DRUG:** Glucagon-like peptide 1 agonist

## Key facts

- **NCT ID:** NCT03807440
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-26
- **Primary completion:** 2021-08-31
- **Final completion:** 2021-08-31
- **Target enrollment:** 4083 (ACTUAL)
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03807440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03807440, "DIA_CENTRAL:T2D Treatment Pattern in Central Europe". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03807440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*